Clinical assessment of a low-dose oestrogen, low-dose progestogen combined oral contraceptive

Abstract

SummaryResults of experience with a low oestrogen, low progestogen combined oral contraceptive in 99 women over a period of 18 months indicate that a reduction in oestrogen and progestogen is associated with good cycle control and efficacy. Although intermenstrual bleeding and amenorrhoea were noted in early cycles, there was a decrease in the usual incidence of headache, nausea, vomiting and depression. The preparation used in the trial, 150 μg. d-norgestrel (as the dl-racemate) and 30 μg. ethinyl oestradiol proved acceptable to the majority of subjects.